Compositions for the treatment or prevention of drug-resistant tumours

Overview

HKBU has developed compositions for the treatment or prevention of drug-resistant tumors, particularly those resistant to BRAF V600E inhibitors. This invention focuses on a combination of oxymatrine and artesunate, which exhibits synergistic effects in inhibiting tumor growth, especially melanoma resistant to BRAF V600E inhibitors, while being safe for normal cells.

  • Compositions for the treatment or prevention of drug-resistant tumours 0
Commercialisation opportunities
Non-exclusive licensing
Problem addressed

This invention addresses the problem of drug resistance in tumors, specifically those resistant to BRAF V600E inhibitors (e.g., vemurafenib, dabrafenib).

Innovation
  • The current invention uses the combination of oxymatrine and artesunate demonstrates a synergistic effect in inhibiting tumor growth, particularly in melanoma resistant to BRAF V600E inhibitors. 
Key impact
  • Maintain safety for normal cells
  • Overcomes Drug Resistance: Targets tumors resistant to BRAF V600E inhibitors (e.g., vemurafenib, dabrafenib) and even MEK inhibitor combinations.
Application
  • The pharmaceutical composition can be administered in various forms, including tablets, capsules, injections, and oral liquids.

Patent

  • China Patent Publication No.: CN 118340776 A
Enquiry
Related Innovations